Literature DB >> 6206500

Specific regulation of c-myc oncogene expression in a murine B-cell lymphoma.

J E McCormack, V H Pepe, R B Kent, M Dean, A Marshak-Rothstein, G E Sonenshein.   

Abstract

The c-myc oncogene has been implicated in a wide spectrum of B-cell neoplasias. In normal cells, the level of expression of the c-myc gene correlates with growth status. In the present study, we examined the effect of receptor-mediated inhibition of growth on c-myc expression in a B-cell lymphoma. The murine lymphoma line WEHI 231 has been characterized as an early B cell; it bears surface-bound IgM and has unrearranged c-myc genes. Following treatment of a WEHI 231 culture with anti-mouse Ig antiserum, the cells undergo one round of division and further proliferation is inhibited. We observed that this treatment specifically affected cytoplasmic levels of c-myc mRNA. An initial early increase is followed by a precipitous drop such that by 4 hr (after exposure) the amount of c-myc mRNA is below control values by a factor of approximately equal to 10. The drop in c-myc precedes cessation of DNA synthesis. During the 2- to 4-hr period, c-myc mRNA had a maximal half-life of between 20 and 30 min. In contrast, even 24 hr after anti-Ig exposure, the amounts of most major mRNAs, including mu heavy chain and actin, were not significantly altered. These results indicate that expression of an unrearranged c-myc gene can be selectively responsive to receptor-mediated regulatory events.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206500      PMCID: PMC391743          DOI: 10.1073/pnas.81.17.5546

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  Functional subsets of murine and human B lymphocyte cell lines.

Authors:  P Ralph
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 2.  Modification of B lymphocyte differentiation by anti-immunoglobulins.

Authors:  A R Lawton; M D Cooper
Journal:  Contemp Top Immunobiol       Date:  1974

3.  Accessory cell requirement for anti-IgM-induced proliferation of B lymphocytes.

Authors:  P Mongini; S Friedman; H Wortis
Journal:  Nature       Date:  1978-12-14       Impact factor: 49.962

4.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

5.  Activation of the c-myc gene by translocation: a model for translational control.

Authors:  H Saito; A C Hayday; K Wiman; W S Hayward; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

6.  Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3' ends.

Authors:  F W Alt; A L Bothwell; M Knapp; E Siden; E Mather; M Koshland; D Baltimore
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

7.  Mechanisms of clonal abortion tolerogenesis. II. Clonal behaviour of immature B cells following exposure to anti-mu chain antibody.

Authors:  G J Nossal; B L Pike; F L Battye
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

8.  The regulation of growth and differentiation of a murine B cell lymphoma. I. Lipopolysaccharide-induced differentiation.

Authors:  A W Boyd; J W Goding; J W Schrader
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

9.  Activation of mouse lymphocytes by anti-immunoglobulin. II. A thymus-independent response by a mature subset of B lymphocytes.

Authors:  D G Sieckmann; I Scher; R Asofsky; D E Mosier; W E Paul
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

10.  Activation of murine B lymphocytes by anti-immunoglobulin is an inductive signal leading to immunoglobulin secretion.

Authors:  D C Parker; D C Wadsworth; G B Schneider
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

View more
  31 in total

1.  An antisense promoter of the murine c-myc gene is localized within intron 2.

Authors:  D B Spicer; G E Sonenshein
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

2.  Transcriptional and posttranscriptional control of c-myc during myogenesis: its mRNA remains inducible in differentiated cells and does not suppress the differentiated phenotype.

Authors:  T Endo; B Nadal-Ginard
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

3.  Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells.

Authors:  M Wu; M Arsura; R E Bellas; M J FitzGerald; H Lee; S L Schauer; D H Sherr; G E Sonenshein
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

4.  Target sequences for cis-acting regulation within the dual promoter of the human c-myc gene.

Authors:  M Lipp; R Schilling; S Wiest; G Laux; G W Bornkamm
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

5.  Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter.

Authors:  M P Duyao; A J Buckler; G E Sonenshein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.

Authors:  Charles M Chau; Xiao-Yong Zhang; Steven B McMahon; Paul M Lieberman
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Models and mechanisms for signal transduction in B cells.

Authors:  C A Pennell; D W Scott
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

8.  Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis.

Authors:  T C Martins; A P Aguas
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

9.  Antigen receptor-induced cell cycle arrest in WEHI-231 B lymphoma cells depends on the duration of signaling before the G1 phase restriction point.

Authors:  D M Page; A L DeFranco
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

10.  JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells.

Authors:  Sergio D Catz; Bernard M Babior; Jennifer L Johnson
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.